{"name":"Kubota Vision Inc.","slug":"kubota-vision-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ACU-4429","genericName":"ACU-4429","slug":"acu-4429","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"ACU-4429","genericName":"ACU-4429","slug":"acu-4429","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxPWE5PeDl6VGpTS2dfMDZUcVk1STN4LUhpdkJwS19NX0RCamlac2NzbGw5N3hkdTg1Q2xUd1VHLWZTQjdpLXlIdXhycFIycnMwSWxxRXlVcDNMblQtTEVnRjlSXzdvNHVzUThNN3VBMExMRnB0QmlhUmRWSXh0Y1RiZnhka3ZNTmtHekcydVJoSXNGS3EzM2RBNExyRVhuMTh0SzdFc1JGdzBKRVNTNVRnamlTQkYxQXlQOTczUzl3aEZ2WDZ1WUJfZllBb0diSWZmMDJBUFpsdzNIak9UcWRNREYzdll2SjJWT2ZORFBxQkdSWk1tRGww?oc=5","date":"2026-03-03","type":"deal","source":"Citeline News & Insights","summary":"Deal Watch: Esperion Augments Cardiovascular Franchise Via Corstasis Buyout - Citeline News & Insights","headline":"Deal Watch: Esperion Augments Cardiovascular Franchise Via Corstasis Buyout - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQWDVVT0I3X1p5NmhLaFpnNkMyMzEtX3pYb3RQd25VamMzbnlwVWFyTFFvVk9NaHhrY0tDSzFzQy1xaGpJdmxmdWJ6TW9EUjdPZFNWODNremFrZjUxX2NxZWpFMVIza2JVUFdvWXExMTV4MXBHY2REeUN4bmtRSmhYSy0yWVcybHZUaWNESGFNc042LWhHcTd4N3E1RFZnOFFWU0xIT1Q5SFMwTGhNRk9tay00MlRzcjdHLUFBamJNSXZmTzV2V1RxekhqU3poSl9F?oc=5","date":"2026-02-25","type":"regulatory","source":"BioCentury","summary":"Rare disease spotlight: Stargardt’s first approval in sight as next-gen aims to restore vision - BioCentury","headline":"Rare disease spotlight: Stargardt’s first approval in sight as next-gen aims to restore vision","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxNcExXbDRXdE1YUnpjU1pBS0UxeTdfb25MRWRWTjF5Q2ZkVGZqZ0hUckt4cmt5clVQaUZpVHQ5dnBYMzl0SDRfTEItdTZyc0lLVlA0VzdlZ2Eyc0ZOVHVqd0dETjNyaVNobkJBbGZldnhCYUE2R3VLS1ZyRWZMUUxHdjBMbTJTYzl2aFdBVXkwdjZrclVFMW55cU84SExpMEpLUm9wNHhWcHVUcjBMZEs1cXFJWXprYm9nV0pnbkJyVGlLc3ZFc2tmQW9RbndjRC1RY1VXaEZPUHBYMnUwWnhkd213ZWlOaHJRM3llY1BKOFlDSUQ1WjdFWTNKcGhoTlFxWnlsV3FtRlFSazlsS29palVfWWp2TDNNOENaR09YelpKMDVCbnR3M3VON1dNVmt3RkI0eVJ6U21wRE0xUzhrWFk4b3VpUFlMdjJOQ1BMbEFrREE?oc=5","date":"2026-01-23","type":"regulatory","source":"Barchart.com","summary":"Stargardt Disease Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics - B","headline":"Stargardt Disease Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveIn","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2025-11-02","type":"earnings","source":"Mint","summary":"Q2 results 2025: Bharti Airtel, SBI, LIC, Paytm, Adani Ent, M&M among companies to declare earnings next week - Mint","headline":"Q2 results 2025: Bharti Airtel, SBI, LIC, Paytm, Adani Ent, M&M among companies to declare earnings next week","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxOWEEwMWRvNWNMbHlRMzI1Sm42bEtQWTlQSWV2VnJGZGNxeG9PNEJQalI0M25PbWNWMnItOWNST2I4RkVleGJrNjJQUHFiNG51VFRXS01ZRWRqdVlodjBhZzRyM1dRcmhtUUNFZTMtN0ZZbjBKcTNnU3lQOWJhaFZlQ1NPN2dnaUJ4WWJFUlhOXzJGenpjaEM2bWM3d09hdnNvdmVzT0ptWEc1WXRNMEpJOUhzU0wxdEw0eHBIUW5MLXJIYXhYMjVka3JDaThYWEVuT2hDSThkdmFVcUVsaUFKR2Vlb2pHeWFOanRYZEdpN1pmZTRyZ2tERkd3cGRnajhMXy1aX0tMUi1sSmZyRXpQZlcxOHRLTzFKUmk5elZTSkpPNW9mdnpxSHI0SC1ISWc?oc=5","date":"2025-10-07","type":"pipeline","source":"prnewswire.com","summary":"Japanese Innovation Comes to Thailand: Revolutionary Myopia Management Device Kubota Glass Debuts at ASEAN International Optics Fair Bangkok 2025 - prnewswire.com","headline":"Japanese Innovation Comes to Thailand: Revolutionary Myopia Management Device Kubota Glass Debuts at ASEAN International","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-07","type":"pipeline","source":"ANI News","summary":"Revolutionary Myopia Management Technology Expands Across Asia -- Kubota Glass Makes Global Debut at ASEAN International Optics Fair Bangkok 2025 - ANI News","headline":"Revolutionary Myopia Management Technology Expands Across Asia -- Kubota Glass Makes Global Debut at ASEAN International","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE9Fb0ZkQk5xVllBT00zNVp3LTYyeXk1QzhJeFpEdGtENUx5TU5jb2RSaE1xSk9TX09nNkF4Ymh2ckRGOUM4OUdvMW9EZ1ZZd3RpZUYzRFpkWUJhc05Fd09sVzF3ekdLVmtSRmNmdThOVkRmV1Npa3hYb1g1SQ?oc=5","date":"2025-06-06","type":"regulatory","source":"Market.us","summary":"Macular Edema and Macular Degeneration Market - Market.us","headline":"Macular Edema and Macular Degeneration Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxOWnFwcEFyaWluNXNacFJfeWQ2NVdsUjEzRG1YeS1TWDUzQ01vYzBtN1lSOHNZMGRjREktdEdBOWV6U2l6QUwtLTI0MVFpekxyTFM0NDZVSkJmN0RKSlZ5bWRDMnNCeWJjNGtER3hJaUE1YjdyVExDeEdEamd2Mi1LcncyTDBHdl9tdl9YWlRXSEh0ZERXVzRTMEkzbkY3V29CMmFVdW1uV2p3NHNkVmNXdE9aUDU1VGV4ZGVXeVpFVXVJY1dydjIxclA3MkFkeGlvem9SUjB0dlRFZlBlWXJ5NDFCalBpSmk5VkhpUl9fT3pHSUdGZGU1YTRhSzZwWnNMQUlCWkZLSXJGbE1mX1NZ?oc=5","date":"2024-11-19","type":"pipeline","source":"GlobeNewswire","summary":"Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight - GlobeNewswire","headline":"Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNWE9jWE9uQnV4LWVhcVloU1dxcndOSlZtWHlDLUVtbXNFVGE5elFsUnFSTkVZLVItdUFHamtQeDEzU3hNbVBxVzJST0pnR09RemJYcWlWclFKWTF4SU81MGJIdUNQQUZHdVZINFZiSWJVaXJZZzhRSDRMMnIyNG5rRXgwMUhWWXpCeEE?oc=5","date":"2024-05-21","type":"pipeline","source":"Grand View Research","summary":"Ophthalmic Devices Industry: A $10.27Bn Ultrasound Systems Opportunity - Grand View Research","headline":"Ophthalmic Devices Industry: A $10.27Bn Ultrasound Systems Opportunity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNcUMwWTg1c0VxQmlQcHdNb3NpZ3dfaUx6TnEzdFI0MFpoVnFTeDViWm9sUk5pRERGQkxfQ05IQkhCTk1WeFZZbFU4S1VCQ1B5ckw3X1dpcUsyREpjMjNPMmZ6VmVGQUxLcUdUUHZ4dzA2Rk1WcndUS1lGek41SzBfTWVPUFhHNS1VT3pzTVNOdzc4WF9BXzkyekxGWXFFbUxxZ1dLMW5rNy00SkwtOEJSdmN1aw?oc=5","date":"2023-12-07","type":"deal","source":"Ophthalmology Times","summary":"Kubota Vision announces multiple partnerships around its eyeMO OCT device - Ophthalmology Times","headline":"Kubota Vision announces multiple partnerships around its eyeMO OCT device","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQb0RtS2pvbXh2dDZqQ3FWdmx0XzQ2R3dvREVfbzZqMTFFUjNVYU9mX051U182X1ktM2RUVUpMQjVCaVZWQ0dTaHhBSjYtSWRDSmhUOTU5MHA5RGVFT2hCQnpjSjl4UDZDV2s1dldNb29jLUtVMDNwLXl6NjNveDdKaE56X3lhQzRKQjJXaF96VnR5QXA2X1E?oc=5","date":"2023-08-04","type":"trial","source":"globaldata.com","summary":"Juvenile Macular Degeneration (JMD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape - globaldata.com","headline":"Juvenile Macular Degeneration (JMD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1aaEYtazJJVUo2YnlETXo4SlhDTTJXdXZvQUZ4NWZZU1RfMmlyOV8yaFRGd2o5ODVZMFlDUDNVeFV3dTh6TUJVM1poRFI5S3VKcXk3YXFCTDg3M3Qtd0Uw?oc=5","date":"2022-07-13","type":"pipeline","source":"Nature","summary":"Biometric and refractive changes following the monocular application of peripheral myopic defocus using a novel augmented-reality optical system in adults - Nature","headline":"Biometric and refractive changes following the monocular application of peripheral myopic defocus using a novel augmente","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}